Meyka Pro banner
Cibus, Inc.

Cibus, Inc. Fundamental Analysis (NASDAQ: CBUS)

CBUSNASDAQ
HealthcareBiotechnology
$1.70
$0.00(0.00%)
U.S. Market opens in 5h 5m

Cibus, Inc. Fundamental Analysis (NASDAQ: CBUS)

Cibus, Inc. (NASDAQ: CBUS) shows weak financial fundamentals with a PE ratio of -1.18, profit margin of -22.59%, and ROE of -3.21%. The company generates $0.0B in annual revenue with weak year-over-year growth of -14.62%.

Key Strengths

Cash Position15.66%
PEG Ratio-0.01
Current Ratio1.62

Areas of Concern

ROE-3.21%
Operating Margin-12.41%
We analyze CBUS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2022.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2022.2/100

We analyze CBUS's fundamental strength across five key dimensions:

Efficiency Score

Weak

CBUS struggles to generate sufficient returns from assets.

ROA > 10%
-31.33%

Valuation Score

Excellent

CBUS trades at attractive valuation levels.

PE < 25
-1.18
PEG Ratio < 2
-0.01

Growth Score

Moderate

CBUS shows steady but slowing expansion.

Revenue Growth > 5%
-14.62%
EPS Growth > 10%
74.33%

Financial Health Score

Moderate

CBUS shows balanced financial health with some risks.

Debt/Equity < 1
2.21
Current Ratio > 1
1.62

Profitability Score

Weak

CBUS struggles to sustain strong margins.

ROE > 15%
-320.60%
Net Margin ≥ 15%
-22.59%
Positive Free Cash Flow
No

Key Financial Metrics

Is CBUS Expensive or Cheap?

P/E Ratio

CBUS trades at -1.18 times earnings. This suggests potential undervaluation.

-1.18

PEG Ratio

When adjusting for growth, CBUS's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Cibus, Inc. at 8.89 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.89

EV/EBITDA

Enterprise value stands at -2.01 times EBITDA. This is generally considered low.

-2.01

How Well Does CBUS Make Money?

Net Profit Margin

For every $100 in sales, Cibus, Inc. keeps $-22.59 as profit after all expenses.

-22.59%

Operating Margin

Core operations generate -12.41 in profit for every $100 in revenue, before interest and taxes.

-12.41%

ROE

Management delivers $-3.21 in profit for every $100 of shareholder equity.

-3.21%

ROA

Cibus, Inc. generates $-31.33 in profit for every $100 in assets, demonstrating efficient asset deployment.

-31.33%

Following the Money - Real Cash Generation

Operating Cash Flow

Cibus, Inc. generates limited operating cash flow of $-45.80M, signaling weaker underlying cash strength.

$-45.80M

Free Cash Flow

Cibus, Inc. generates weak or negative free cash flow of $-46.06M, restricting financial flexibility.

$-46.06M

FCF Per Share

Each share generates $-0.60 in free cash annually.

$-0.60

FCF Yield

CBUS converts -35.28% of its market value into free cash.

-35.28%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.18

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.89

vs 25 benchmark

P/S Ratio

Price to sales ratio

30.11

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.21

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.62

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-3.21

vs 25 benchmark

ROA

Return on assets percentage

-0.31

vs 25 benchmark

ROCE

Return on capital employed

-0.18

vs 25 benchmark

How CBUS Stacks Against Its Sector Peers

MetricCBUS ValueSector AveragePerformance
P/E Ratio-1.1831.61 Better (Cheaper)
ROE-320.60%541.00% Weak
Net Margin-2258.89%30180.00% Weak
Debt/Equity2.210.54 Weak (High Leverage)
Current Ratio1.625.70 Neutral
ROA-31.33%-8.00% (disorted) Weak

CBUS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Cibus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-77.40%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-319.77%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-71.56%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ